Genprex Gains Australian Patent Acceptance for REQORSA Therapy

Genprex ( (GNPX) ) has shared an update.

On February 10, 2026, Genprex announced that IP Australia issued a Notice of Acceptance on February 5, 2026, for its patent application covering the use of REQORSA Gene Therapy with PD-L1 antibodies for cancer treatment. If granted, the patent would extend Genprex’s exclusivity for this combination to Australia, reinforcing an intellectual property portfolio that already includes similar protections in the U.S. and Korea and complementing its broader global patent strategy.

The company also reported that it has opened an additional site at the University of Kentucky for its Acclaim-3 Phase 1/2 trial of REQORSA plus Tecentriq as maintenance therapy in extensive stage small cell lung cancer. Following a generally well-tolerated Phase 1, the Phase 2 expansion aims to enroll about 50 patients with an interim analysis planned after 25 patients in 2026, a step expected to accelerate trial enrollment under existing Fast Track and Orphan Drug designations.

More about Genprex

Genprex, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for cancer, with a key emphasis on lung cancer. Its lead candidate, REQORSA Gene Therapy, is being evaluated in combination with immunotherapies such as PD-L1 antibodies and Genentech’s Tecentriq, targeting patients with extensive stage small cell lung cancer and other malignancies.

Average Trading Volume: 740,209

Technical Sentiment Signal: Sell

Current Market Cap: $5.1M

For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.